To date, targeted molecular inhibitors for GC, such as PARP inhibitors, PI3K / AKT / mTOR inhibitors, EZH2 inhibitors, and others, have been investigated extensively based on ARID1A gene mutation or defect combined with the concept of synthetic lethality. This evidence concerns the gene ARID1A and gastric cancer.